Home » About Cutaquig®

About cutaquig®

Indication and clinical use

Cutaquig® is indicated for the treatment of patients with primary immune deficiency (PID) and secondary immune deficiency (SID) who require immune globulin replacement therapy.


Cutaquig® is contraindicated in patients who are hypersensitive to this drug or to any ingredient in the
formulation or component of the container. Cutaquig® is contraindicated in patients who have had an anaphylactic or severe systemic reaction to the administration of human IgG or to components of cutaquig® such as maltose or polysorbate 80.

Most serious warnings and precautions

Anaphylactic Reaction: Rarely, human normal immunoglobulin can induce a fall in blood pressure with anaphylactic reaction, even in patients who had tolerated  previous treatment with human normal immunoglobulin. Suspicion of allergic or anaphylactic type reactions requires immediate discontinuation of the injection. In case of shock, standard medical treatment should be administered.

Thromboembolic Events: There is clinical evidence of an association between the administration of immunoglobulins and thromboembolic events such as myocardial infarction, stroke, pulmonary embolism and deep vein thrombosis. Therefore, caution should be exercised when prescribing and administering immunoglobulins. Risk factors for thromboembolic events include: advanced age, use of estrogens, in-dwelling central vascular catheters, history of vascular disease or thrombotic episodes, acquired or inherited hypercoagulable states, prolonged periods of immobilization, severe hypovolemia, diseases which increase blood viscosity and cardiovascular risk factors (including obesity, hypertension, diabetes mellitus, history ofatherosclerosis and/or impaired cardiac output).

Thrombosis: Thrombosis may occur even in the absence of known risk factors. The physician should discuss the risks and benefits of this product the patient, before prescribing or administering to the patient.

Other relevant warnings and precautions

Products made from human plasma may contain infectious agents, such as viruses and theoretically, the variant Creutzfeldt-Jakob disease (vCJD) agent that can cause disease. The risk that such products will transmit an infectious agent has been reduced by screening plasma donors for prior exposure to certain viruses, screening of individual donations and plasma pools for specific markers of infection and the inclusion of effective manufacturing steps for the inactivation/removal of viruses.

Rarely, human normal immunoglobulin can induce a fall in blood pressure with anaphylactic reaction, even in patients who had tolerated previous treatment with human normal immunoglobulin. In case of hypersensitivity, discontinue the cutaquig® infusion immediately and institute appropriate treatment.

Severe hypersensitivity or anaphylactic reactions up to shock can particularly occur in patients with known allergies to anti-IgA antibodies. Patients with anti- IgA antibodies may have a greater risk of developing potentially severe hypersensitivity and anaphylactic reaction with the administration with cutaquig®. Close medical supervision is required. In case of severe hypersensitivity/ anaphylactic reactions the administration of cutaquig® must be stopped immediately. In case of shock, standard medical treatment should be administered.
Aseptic Meningitis Syndrome (AMS) has been reported with use of IVIG or SCIG. The syndrome usually begins within several hours to 2 days following immune globulin treatment. AMS is characterized by the following signs and symptoms: severe headache, neck stiffness, drowsiness, fever, photophobia, nausea, and vomiting. Patients exhibiting signs and symptoms of AMS should receive a thorough neurological examination, including CSF studies, to rule out other causes of meningitis. Discontinuation of immunoglobulin treatment may result in remission of AMS within several days without sequelae.
Individuals with IgA deficiency can develop anti-IgA antibodies and in very rare cases develop potentially severe hypersensitivity and anaphylactic reactions after administration of blood components containing IgA. Not all patients with anti-IgA antibodies receiving IVIG experience reactions, but those patients with high or rising titers of anti-IgA antibodies are thought to have an increased risk of adverse reactions. Patients who have experienced adverse reactions to IVIG have been reported to better tolerate SCIG. Patients with anti-IgA antibodies, in whom treatment with subcutaneous IgG products remains the only option, should be given cutaquig® only under close medical supervision.
Pregnant women

The safety of cutaquig® for use in human pregnancy has not been established in controlled clinical trials. Cutaquig® should be given to pregnant women only if clearly needed.

Nursing women

cutaquig® has not been evaluated in nursing mothers. After administration of IVIG products, IgGs are excreted into the milk and may contribute to the transfer of protective antibodies to the neonate.


(< 18 years of age): In the Pivotal Phase III study there were no apparent differences in the safety and efficacy profiles of pediatric subjects as compared with adult subjects being treated with cutaquig®. No pediatric- specific dose requirements were necessary to achieve the desired serum IgG levels. Cutaquig® was not studied in neonates or infants.


(> 65 years of age): In the Pivotal Phase III study, 3 patients over 65 years of age were evaluated. The pivotal clinical study did not include sufficient number of subjects over the age of 65 years to determine whether they respond differently from younger patients. No overall differences in safety profile or efficacy are to be expected between these subjects and younger subjects.

Adversed drug reactions overview

No related serious adverse drug reactions were observed in subjects treated with cutaquig® during the clinical studies evaluating its safety profile. The most common related adverse drug reactions reported in patients treated with cutaquig® were local reactions at the site of injection (71.2%) and pyrexia (3.4%).

*Cutaquig® Canadian Product Monograph, approved on June 9, 2022

Adverse events should be reported to

Legal Statement

This website & the Websites at which these Terms and Conditions of Use are posted (collectively, the “Websites”) are created and controlled by Octapharma Canada Inc. (hereinafter “Octapharma” or “we” or “us”). By using these websites you agree to abide by the terms and conditions set out below and all applicable laws. If you do not agree to abide by these terms and conditions, do not use these websites.

Informational Purposes Only

Product information on our websites is provided by Octapharma and is intended for general information purposes only, for residents in Canada. The products listed are available upon prescription from a medical doctor or qualified medical professional. The product related information is furthermore not intended to provide complete medical information. You should always obtain complete medical information about your prescription medicines or medical devices (including their beneficial medical uses and possible adverse effects) by discussing the appropriate use of any medicine/medical devices directly with your prescribing physician or, where appropriate, other medical advisor. Medical professionals may obtain complete medical information from the product monograph.

Copyright protection

Copyright in all material contained on our websites are owned by Octapharma, unless otherwise indicated.

Octapharma reserves all rights in the content and design of our websites. Unless permitted in writing by Octapharma, you may not reproduce, use or copy any content on this website including names, logos, designs, product information and any other material/information used in this website (hereinafter together referred to as the “Information”). You may not use commercially any Information, and you may not cause any of the Information to be framed or embedded into another website without prior written permission from Octapharma.

All Information referred to in this website is the property of its respective owner and should not be used in whole or in part in any jurisdiction without the prior written consent of its owner. Nor should any graphic that is substantially similar to any trademark, logo or name referred to on this website be so used.

Intellectual property rights

Octapharma hold all intellectual property rights in relation to all products referred to on this website, unless otherwise indicated to the contrary. No representations should be made in relation to the manufacture, sale or distribution of products of the Octapharma group except with the prior written consent of Octapharma.

No warranties or representation

The Information are provided “as is” and without warranties of any kind either express or implied.

To the fullest extent permissible by law, Octapharma expressly disclaims all representations and warranties, express or implied, in connection with or in respect of this website and/or the products referred to on it – including, without limitation any representations or warranties of any kind in relation to:

· The accuracy or completeness of any of the Information contained in this website;

· The accuracy or completeness of any Information contained in any website hyperlinked to this website.

· The therapeutic or other qualities of any products manufactured, supplied or distributed by Octapharma;

· and/or any performance results specified in this website in respect of any products manufactured, supplied or distributed by Octapharma or its related entities.

The Information is provided on the basis that all persons accessing the website undertake the responsibility for assessing the accuracy of its content and that they rely on it entirely at their own risk. Octapharma (including its directors, affiliates, officers, employees, agents, contractors, successors and assigns) does not bear any liability for loss or damages incurred by any person as a result of reliance placed upon the Information or any other information incorporated by reference.

Limitation of liabilities

In no event shall Octapharma (including its directors, affiliates, officers, employees, agents, contractors, successors and assigns) be liable for any direct, indirect, punitive, incidental, special, consequential damages or any damages whatsoever including, without limitation, damages for loss of use, data, profit earnings, or lost opportunities, arising out of or in any way connected with the use or performance of this website.

Third party websites

As a convenience to you, Octapharma may provide links to websites operated by other entities. If you use these websites, you will leave our websites. If you decide to visit any linked website, you do so at your own risk and it is your responsibility to take all protective measures to guard against viruses or other destructive elements.

Octapharma (including its directors, affiliates, officers, employees, agents, contractors, successors and assigns) makes no warranty or representation regarding, and does not endorse, any linked websites or the information appearing thereon or any of the products or services described thereon.

Links do not imply that Octapharma is affiliated or associated with, or is legally authorized to use any trademark, trade name, logo or copyright symbol displayed in or accessible through the links, or that any linked website is authorized to use any trademark, trade name, logo or copyright symbol of Octapharma.

All links to this website must be approved by Octapharma. Octapharma reserves the right to revoke this consent to link at any time in its sole discretion.

Amendments to the website

Octapharma reserves the right to make changes, modifications, additions, deletions and corrections to this website at any time and without notice. Octapharma may also withdraw access to this website at any time without notice.

Virus protection

Octapharma does not warrant or represent that this website or emails received from Octapharma pursuant to the mailing list facility will be uninterrupted or virus free or free of other harmful components. Octapharma (including its directors, affiliates, officers, employees, agents, contractors, successors and assigns) does not bear any responsibility for any damage caused to your equipment as a result of accessing this website, downloading any of the content from this website or receiving emails from Octapharma pursuant to the mailing list facility.

Applicable law

These terms of use as well as the privacy statement and the resolution of any dispute related to these terms of use and/or the privacy statement shall be construed in accordance with the laws of the Province of Ontario and the applicable laws of Canada without any conflict of law rules or principles that may make the laws of another jurisdiction apply.

Last updated: 2021-09-03


Data Privacy Statement

Octapharma Canada Inc (hereinafter “Octapharma” or “we” or “us”) respects the right of individuals regarding their personal data and is committed to protecting your personal information and complying with Canada’s Personal Information Protection and Electronic Documents Act.

This Data Privacy Statement (“statement”) describes the way we process your personal information when you visit our websites. Personal information is information that identifies you as an individual, for example, your e-mail address.

What information is collected and why?

Your use of our website does not generally require you to provide us with personal information. However, we may collect personal information that you voluntarily provide us through responses to questionnaires, surveys, feedback forms, or who participate in our online health assessment tools, contests, chat rooms or other discussion forums. In addition, certain sections of our website are restricted and may require registration prior to access.

You may also be asked to provide additional information such as your e-mail address if you want to obtain additional services or information. If you have given separate consent to receive information in this way, the information may be sent by e-mail. If you later change your mind about such use for any reason, you may withdraw your consent to that use by contacting Octapharma Canada Inc, as set forth below.

When you submit information to our website, you agree that we may collect, use and disclose that information for the purpose(s) specified in those sections of the website and in accordance with the terms and conditions of this privacy statement. If you do not agree to these terms, please do not submit information to our website.

We may use information gathered about you in aggregate for the following purposes: to monitor interest in our products and services, to help tailor the content of our sites to your needs by collecting information about your preferences through tracking of pattern page views on our sites; to create a profile relating to you in order to show you the content that might be of interest to you and to display the content according to your preferences.


In order to properly manage our websites, we may log information and identify categories of visits by items such as domain name, browser type and version, the pages visited within the Octapharma sites and the URL to which the user goes upon leaving Octapharma’s site to continuously improve the performance of our website. We do this through the use of “cookies” and other site-usage information technologies. This information is used in an aggregate form only and personal data is therefore anonymized.

Cookies are pieces of data that a website can transfer to a user’s web browser. The cookies may remain on your computer after you leave the website but you can manually delete them using most browsers. Most web browsers are pre-set to accept cookies.

When you visit our sites, if your browser is using the standard settings and it is accepting cookies, you are giving consent for cookies on this site to be stored on your computer. If you prefer not to receive cookies, you can adjust your web browser to refuse cookies or to warn you when cookies are being used. Most elements of our sites will still function if you disable cookies in your web browser settings.

Disclosure of personal information

Octapharma will not disclose personal information to any third parties except: i) in accordance with this privacy statement, or ii) to comply with legal requirements, and/or iii) if you are reporting a side effect relating to one of Octapharma’s products which must be reported to regulatory authorities. We may share information within Octapharma and with companies working with Octapharma for purposes that you have authorized, and under the terms of this privacy statement. Service providers to Octapharma are required to comply with this privacy statement when using your personal information. Octapharma also reserves the right to disclose or transfer personal information in connection with a business transaction, such as the sale or merger of a business.

For any storage or processing of personal information outside of Canada, local privacy laws may require the disclosure of personal information to governmental authorities under circumstances that are different than those that apply in Canada.

Protection of information

Physical, electronic, and managerial procedures are in place to prevent unauthorized access or use of personal information and to maintain data security.

Personal information you share with us is stored on Octapharma servers, including outside of Canada, or hosted by third parties bound by this privacy statement. We have implemented technological measures to prevent individuals from accessing information without authorization. Data centers are designed to be physically secure and protected from unauthorized access by unauthorized persons. Information is stored for as long as is necessary to fulfil the purposes for which the information was collected and to comply with legal requirements.

Contacting us

To contact us with questions about this privacy statement or about Octapharma’s handling of your personal information, please contact our Data Protection Coordinator at: Octapharma Canada Inc., 214 King St W, Toronto, ON M5H 3S6, Attention: Data Protection Coordinator

We may update or amend this statement at any time by posting the amended statement to the website. By using this site, you agree to the Terms and the privacy statement.

Last updated: 2021-09-03